Ampio Pharmaceuticals Inc (AMPE) Director Acquires $16,800.00 in Stock
Ampio Pharmaceuticals Inc (NASDAQ:AMPE) Director Philip H. Coelho bought 30,000 shares of the company’s stock in a transaction dated Tuesday, September 5th. The shares were acquired at an average cost of $0.56 per share, with a total value of $16,800.00. Following the acquisition, the director now directly owns 75,727 shares of the company’s stock, valued at $42,407.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Ampio Pharmaceuticals Inc (AMPE) traded up 2.885% during midday trading on Thursday, hitting $0.535. 360,012 shares of the stock were exchanged. The stock’s market cap is $36.50 million. Ampio Pharmaceuticals Inc has a one year low of $0.38 and a one year high of $1.14. The firm has a 50-day moving average price of $0.51 and a 200-day moving average price of $0.65.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/09/07/ampio-pharmaceuticals-inc-ampe-director-acquires-16800-00-in-stock.html.
Ampio Pharmaceuticals Company Profile
Ampio Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The Company’s two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema.
Receive News & Ratings for Ampio Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.